Effects of Qingda granule on patients with grade 1 hypertension at low-medium risk: study protocol for a randomized, controlled, double-blind clinical trial
This study aims to evaluate the efficacy and safety of QDG in reducing blood pressure among patients with grade 1 hypertension at low-medium risk.MethodsThe study is designed as a randomized, multi-center, double-blinded, non-inferiority clinical trial. Five hundred fifty-two patients with grade 1 hypertension at low-medium risk from 13 hospitals will be recruited and randomly assigned to the QDG group (n = 276, treated with valsartan capsule simulation agent and QDG) or control group (n = 276, treated with valsartan capsule and QDG simulation agent). The treatment period will be 4 weeks and the follow-up period will last ...
Source: Trials - January 2, 2023 Category: Research Source Type: clinical trials
Sacubitril/Valsartan Treated Adult Patients With Chronic Heart Failure
Condition: Chronic Heart Failure Intervention: Drug: sacubitril/valsartan Sponsor: Novartis Pharmaceuticals Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 14, 2022 Category: Research Source Type: clinical trials
Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease
Condition: Diabetic Kidney Disease Interventions: Drug: SPH3127+SPH3127matching placebo+valsartan matching placebo; Drug: SPH3127+valsartan matching placebo; Drug: SPH3127 matching placebo+valsartan Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 25, 2022 Category: Research Source Type: clinical trials
